TABLE 1.
Demographics and baseline clinical characteristics of patients in the two treatment groups.
| Characteristics | CQC Group (n = 25) | Control Group (n = 25) |
|---|---|---|
| Gender, male: n (%) | 13 (52.0%) | 12 (48.0%) |
| Age, years: mean (SD) | 41.4 (12.9) | 46.4 (12.4) |
| Age, years: median (IQR) | 43.0 (32.0, 51.0) | 45.0 (37.0, 52.0) |
| Age, years: (min, max) | (20.0, 66.0) | (23.0,76.0) |
| Age category (years) | ||
| 18–30 | 5 | 2 |
| 31–55 | 18 | 18 |
| >55 | 2 | 5 |
| Comorbidity | 8 (32.0%) | 13 (52.0%) |
| DM and/or HTN | 8 (32.0%) | 12 (48.0%) |
| Other | - | 1 (4.0%) |
| Acute COVID-19 symptoms | ||
| Fever | 18 (72.0%) | 22 (88.0%) |
| Pharyngitis | 14 (56.0%) | 12 (48.0%) |
| Cough | 14 (56.0%) | 13 (52.0%) |
| Myalgia | 12 (48.0%) | 12 (48.0%) |
| Flu | 5 (20.0%) | 2 (8.0%) |
| Dyspnea | 2 (8.0%) | 5 (20.0%) |
| ≥3 COVID-19 symptoms | 17 (68.0%) | 16 (64.0%) |
| COVID-19 vaccination | 13 (52.0%) | 16 (64.0%) |
| Azithromycin in SOC | 17 (34.0%) | 16 (32.0%) |